<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MOBIC- meloxicamÂ suspensionÂ </strong><br><strong>MOBIC- meloxicamÂ tabletÂ </strong><br>Boehringer Ingelheim Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information
needed to use MOBIC safely and effectively.  See full prescribing
information for MOBIC. <br>MobicÂ® (meloxicam) tablets <br>MobicÂ® (meloxicam) oral suspension<br>Initial U.S. Approval:
2000</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING: CARDIOVASCULAR and
GASTROINTESTINAL RISKS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics"><span class="Emphasis">See full prescribing
information for complete boxed warning.</span></span></span></h1>
<p class="ListCaption">Cardiovascular Risk</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">NSAIDs may cause an increased risk of serious
cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>,
which can be fatal. This risk may increase with duration of use. Patients
with cardiovascular disease or risk factors for cardiovascular disease
may be at greater risk. (<a href="#Section_5.1">5.1</a>)</span></span><br><br>
</li>
<li><span class="Bold"><span class="Emphasis">MOBIC is contraindicated for the treatment
of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft
(CABG) surgery (<a href="#Section_4.2">4.2</a>, <a href="#Section_5.1">5.1</a>)</span></span></li>
</ul>
<p class="ListCaption">Gastrointestinal Risk</p>
<ul class="Disc"><li><span class="Bold"><span class="Emphasis">NSAIDs cause an increased risk of serious
gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and
perforation of the stomach or intestines, which can be fatal. These
events can occur at any time during use and without warning symptoms.
Elderly patients are at greater risk for serious gastrointestinal
events. (<a href="#Section_5.2">5.2</a>)</span></span></li></ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING: CARDIOVASCULAR and
GASTROINTESTINAL RISKS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics"><span class="Emphasis">See full prescribing
information for complete boxed warning.</span></span></span></h1>
<p class="ListCaption">Cardiovascular Risk</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">NSAIDs may cause an increased risk of serious
cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>,
which can be fatal. This risk may increase with duration of use. Patients
with cardiovascular disease or risk factors for cardiovascular disease
may be at greater risk. (<a href="#Section_5.1">5.1</a>)</span></span><br><br>
</li>
<li><span class="Bold"><span class="Emphasis">MOBIC is contraindicated for the treatment
of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft
(CABG) surgery (<a href="#Section_4.2">4.2</a>, <a href="#Section_5.1">5.1</a>)</span></span></li>
</ul>
<p class="ListCaption">Gastrointestinal Risk</p>
<ul class="Disc"><li><span class="Bold"><span class="Emphasis">NSAIDs cause an increased risk of serious
gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and
perforation of the stomach or intestines, which can be fatal. These
events can occur at any time during use and without warning symptoms.
Elderly patients are at greater risk for serious gastrointestinal
events. (<a href="#Section_5.2">5.2</a>)</span></span></li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">MOBIC is a non-steroidal anti-inflammatory
drug indicated for: </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> (OA) <a href="#Section_1.1">(1.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> (RA) <a href="#Section_1.2">(1.2)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">Juvenile Rheumatoid Arthritis</span> (JRA) in patients 2 years
of age or older <a href="#Section_1.3">(1.3)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Use the lowest effective dose for the shortest
duration consistent with individual treatment goals for the individual
patient. </p>
<ul class="Disc"><li>OA (<a href="#Section_2.2">2.2</a>) and RA (<a href="#Section_2.3">2.3</a>):			<ul class="Circle">
<li>Starting dose: 7.5 mg once daily</li>
<li>Dose may be increased to 15 mg once daily</li>
</ul>
</li></ul>
<ul class="Disc"><li>JRA (<a href="#Section_2.4">2.4</a>): 			<ul class="Circle"><li>0.125 mg/kg once daily up to a maximum of 7.5 mg. JRA dosing
using the oral suspension should be individualized based on the weight
of the child. (<a href="#Section_2.4">2.4</a>)</li></ul>
</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Tablets: 7.5 mg, 15 mg <a href="#Section_3">(3)</a>
</li>
<li>Oral Suspension: 7.5 mg/5 mL <a href="#Section_3">(3)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and
serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>) to meloxicam <a href="#Section_4.1">(4.1)</a>
</li>
<li>History of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or other allergic-type reactions
after taking aspirin or other NSAIDs <a href="#Section_4.1">(4.1)</a>
</li>
<li>Use during the peri-operative period in the setting of coronary
artery bypass graft (CABG) surgery <a href="#Section_4.2">(4.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious and potentially fatal cardiovascular (CV) thrombotic
events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Patients with known CV
disease/risk factors may be at greater risk. <a href="#Section_5.1">(5.1)</a>
</li>
<li>Serious gastrointestinal (GI) adverse events which can be
fatal. The risk is greater in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>
disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and in patients at higher risk for GI events,
especially the elderly. <a href="#Section_5.2">(5.2)</a>
</li>
<li>Elevated liver enzymes, and rarely, severe hepatic reactions.
Discontinue use immediately if abnormal liver enzymes persist or worsen. <a href="#Section_5.3">(5.3)</a>
</li>
<li>New onset or worsening of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure should
be monitored closely during treatment. <a href="#Section_5.4">(5.4)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Should be used with caution in
patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <a href="#Section_5.5">(5.5)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">Renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span> with long-term
use. Use with caution in the elderly, those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>,
<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, and those taking diuretics, ACE-inhibitors,
or angiotensin II antagonists. The use of MOBIC in patients with severe
<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended. <a href="#Section_5.6">(5.6)</a>
</li>
<li>Serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>,
<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN),
which can be fatal and can occur without warning. Discontinue MOBIC
at first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. <a href="#Section_5.8">(5.8)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Most common (â‰¥5% and greater than placebo) adverse events
in adults are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>,
and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms (<a href="#Section_6.1">6.1</a>)</li>
<li>Adverse events observed in pediatric studies were similar
in nature to the adult clinical trial experience (<a href="#Section_6.1">6.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</span></span> </p>
</div>
<div>
<div><div></div></div>
<div><div></div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concomitant use of MOBIC and warfarin may result in increased
risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications <a href="#Section_7.7">(7.7)</a>
</li>
<li>Concomitant use of MOBIC and aspirin is not generally recommended
because of the potential of increased adverse effect including increased
GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a href="#Section_7.2">(7.2)</a>
</li>
<li>Concomitant use with MOBIC increases lithium plasma levels <a href="#Section_7.4">(7.4)</a>
</li>
<li>Concomitant use with NSAIDs may reduce the antihypertensive
effect of ACE-inhibitors <a href="#Section_7.1">(7.1)</a>
</li>
<li>Due to the presence of sorbitol in MOBIC oral suspension,
there may be a risk of <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">intestinal necrosis</span> (possibly fatal) when the
oral suspension is administered concomitantly with sodium polystyrene
sulfonate <a href="#Section_7.8">(7.8)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Based on animal data, may cause fetal harm.  Starting at
30 weeks gestation, MOBIC should be avoided as premature closure of
the ductus arteriosus in the fetus may occur. <a href="#Section_5.9">(5.9</a>, <a href="#Section_8.1">8.1)</a>
</li>
<li>Nursing Mothers: Use with caution, as meloxicam may be excreted
in human milk <a href="#Section_8.3">(8.3)</a>
</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: RISK OF SERIOUS
CARDIOVASCULAR and GASTROINTESTINAL EVENTS</a></h1>
<h1><a href="#section-1" class="toc">1â€ƒâ€ƒINDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1â€ƒâ€ƒOsteoarthritis (OA)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2â€ƒâ€ƒRheumatoid <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>
(RA)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3â€ƒâ€ƒJuvenile Rheumatoid
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> (JRA) Pauciarticular and Polyarticular Course</a></h2>
<h1><a href="#section-2" class="toc">2â€ƒâ€ƒDOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1â€ƒâ€ƒGeneral Instructions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2â€ƒâ€ƒOsteoarthritis</a></h2>
<h2><a href="#section-2.3" class="toc">2.3â€ƒâ€ƒRheumatoid <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4â€ƒâ€ƒJuvenile Rheumatoid
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> (JRA) Pauciarticular and Polyarticular Course</a></h2>
<h1><a href="#section-3" class="toc">3â€ƒâ€ƒDOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4â€ƒâ€ƒCONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1â€ƒâ€ƒAllergic Reactions</a></h2>
<h2><a href="#section-4.2" class="toc">4.2â€ƒâ€ƒCoronary Surgery</a></h2>
<h1><a href="#section-5" class="toc">5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1â€ƒâ€ƒCardiovascular Thrombotic
Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2â€ƒâ€ƒGastrointestinal
(GI) Effects â€“ Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></h2>
<h2><a href="#section-5.3" class="toc">5.3â€ƒâ€ƒHepatic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4â€ƒâ€ƒHypertension</a></h2>
<h2><a href="#section-5.5" class="toc">5.5â€ƒâ€ƒCongestive Heart
Failure and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6â€ƒâ€ƒRenal Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7â€ƒâ€ƒAnaphylactoid Reactions</a></h2>
<h2><a href="#section-5.8" class="toc">5.8â€ƒâ€ƒAdverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9â€ƒâ€ƒPregnancy</a></h2>
<h2><a href="#section-5.10" class="toc">5.10â€ƒâ€ƒCorticosteroid
Treatment</a></h2>
<h2><a href="#section-5.11" class="toc">5.11â€ƒâ€ƒMasking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span>
and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12â€ƒâ€ƒHematological Effects</a></h2>
<h2><a href="#section-5.13" class="toc">5.13â€ƒâ€ƒUse in Patients
with Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14â€ƒâ€ƒMonitoring</a></h2>
<h1><a href="#section-6" class="toc">6â€ƒâ€ƒADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1â€ƒâ€ƒClinical Trials
Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2â€ƒâ€ƒPost Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7â€ƒâ€ƒDRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1â€ƒâ€ƒACE-inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2â€ƒâ€ƒAspirin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3â€ƒâ€ƒDiuretics</a></h2>
<h2><a href="#section-7.4" class="toc">7.4â€ƒâ€ƒLithium</a></h2>
<h2><a href="#section-7.5" class="toc">7.5â€ƒâ€ƒMethotrexate</a></h2>
<h2><a href="#section-7.6" class="toc">7.6â€ƒâ€ƒCyclosporine</a></h2>
<h2><a href="#section-7.7" class="toc">7.7â€ƒâ€ƒWarfarin</a></h2>
<h2><a href="#section-7.8" class="toc">7.8â€ƒâ€ƒKayexalateÂ® (sodium
polystyrene sulfonate)</a></h2>
<h1><a href="#section-8" class="toc">8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1â€ƒâ€ƒPregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2â€ƒâ€ƒLabor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3â€ƒâ€ƒNursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4â€ƒâ€ƒPediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5â€ƒâ€ƒGeriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6â€ƒâ€ƒHepatic Impairment</a></h2>
<h2><a href="#section-8.7" class="toc">8.7â€ƒâ€ƒRenal Impairment</a></h2>
<h2><a href="#section-8.8" class="toc">8.8â€ƒâ€ƒFemales of Reproductive Potential</a></h2>
<h1><a href="#section-9" class="toc">10â€ƒâ€ƒOVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11â€ƒâ€ƒDESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12â€ƒâ€ƒCLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1â€ƒâ€ƒMechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2â€ƒâ€ƒPharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3â€ƒâ€ƒPharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1â€ƒâ€ƒCarcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14â€ƒâ€ƒCLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1â€ƒâ€ƒOsteoarthritis
and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2â€ƒâ€ƒJuvenile Rheumatoid
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> (JRA) Pauciarticular and Polyarticular Course</a></h2>
<h1><a href="#section-14" class="toc">16â€ƒâ€ƒHOW SUPPLIED/STORAGE
AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc"></a></h2>
<h1><a href="#section-15" class="toc">17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1â€ƒâ€ƒMedication Guide</a></h2>
<h2><a href="#section-15.2" class="toc">17.2â€ƒâ€ƒCardiovascular
Effects</a></h2>
<h2><a href="#section-15.3" class="toc">17.3â€ƒâ€ƒGastrointestinal
Effects</a></h2>
<h2><a href="#section-15.4" class="toc">17.4â€ƒâ€ƒHepatotoxicity</a></h2>
<h2><a href="#section-15.5" class="toc">17.5â€ƒâ€ƒAdverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6â€ƒâ€ƒWeight Gain and
<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-15.7" class="toc">17.7â€ƒâ€ƒAnaphylactoid Reactions </a></h2>
<h2><a href="#section-15.8" class="toc">17.8â€ƒâ€ƒEffects During
Pregnancy</a></h2>
<h2><a href="#section-15.9" class="toc">17.9â€ƒâ€ƒEffects on Female Fertility</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-1"></a><p></p>
<h1>WARNING: RISK OF SERIOUS
CARDIOVASCULAR and GASTROINTESTINAL EVENTS</h1>
<p class="First"><a name="p23122"></a></p>
<p class="ListCaption">Cardiovascular Risk</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">Nonsteroidal anti-inflammatory drugs (NSAIDs)
may cause an increased risk of serious cardiovascular (CV) thrombotic
events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This
risk may increase with duration of use. Patients with cardiovascular
disease or risk factors for cardiovascular disease may be at greater
risk [<span class="Italics">see Warnings and Precautions <a href="#Section_5.1">(5.1)</a></span>]</span>.</span><br><br>
</li>
<li><span class="Bold"><span class="Emphasis">MOBIC is contraindicated for the treatment
of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft
(CABG) surgery [<span class="Italics">see Contraindications <a href="#Section_4.2">(4.2)</a> and Warnings and Precautions <a href="#Section_5.1">(5.1)</a></span>]</span>.</span></li>
</ul>
<p class="ListCaption">Gastrointestinal Risk</p>
<ul class="Disc"><li><span class="Bold"><span class="Emphasis">NSAIDs cause an increased risk of serious
gastrointestinal (GI) adverse reactions including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration,
and perforation of the stomach or intestines, which can be fatal.
These events can occur at any time during use and without warning
symptoms. Elderly patients are at greater risk for serious gastrointestinal
events [<span class="Italics">see Warnings and Precautions <a href="#Section_5.2">(5.2)</a></span>]</span>.</span></li></ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1â€ƒâ€ƒINDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1â€ƒâ€ƒOsteoarthritis (OA)</h2>
<p class="First"><a name="p790122"></a>MOBIC is indicated for relief of the signs
and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> [<span class="Italics"><span class="Emphasis">see Clinical Studies <a href="#Section_14.1">(14.1)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2â€ƒâ€ƒRheumatoid <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>
(RA)</h2>
<p class="First"><a name="p807122"></a>MOBIC is indicated
for relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> [<span class="Italics"><span class="Emphasis">see Clinical Studies <a href="#Section_14.1">(14.1)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3â€ƒâ€ƒJuvenile Rheumatoid
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> (JRA) Pauciarticular and Polyarticular Course</h2>
<p class="First"><a name="p1030122"></a>MOBIC is indicated for relief of the signs
and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> in patients 2 years of age and older [<span class="Italics"><span class="Emphasis">see Clinical Studies <a href="#Section_14.2">(14.2)</a></span></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2â€ƒâ€ƒDOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1â€ƒâ€ƒGeneral Instructions</h2>
<p class="First"><a name="p1286122"></a>Carefully consider the potential benefits
and risks of MOBIC and other treatment options before deciding to
use MOBIC. Use the lowest effective dose for the shortest duration
consistent with individual patient treatment goals [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.4">(5.4)</a></span></span>].</p>
<p><a name="p1298122"></a>After
observing the response to initial therapy with MOBIC, adjust the dose
to suit an individual patient's needs.</p>
<p><a name="p1301122"></a>In adults, the maximum recommended daily oral dose of
MOBIC is 15 mg regardless of formulation. In patients with hemodialysis,
a maximum daily dosage of 7.5 mg is recommended [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.6">(5.6)</a>, Use in Specific Populations <a href="#Section_8.7">(8.7)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
<p><a name="p1321122"></a>MOBIC
oral suspension 7.5 mg/5 mL or 15 mg/10 mL may be substituted for
MOBIC tablets 7.5 mg or 15 mg, respectively.</p>
<p><a name="p1324122"></a><span class="Bold"><span class="Emphasis">Shake the oral suspension gently before
using.</span></span></p>
<p><a name="p1537122"></a>MOBIC
may be taken without regard to timing of meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2â€ƒâ€ƒOsteoarthritis</h2>
<p class="First"><a name="p1545122"></a>For the relief of the signs and symptoms
of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> the recommended starting and maintenance oral dose
of MOBIC is 7.5 mg once daily. Some patients may receive additional
benefit by increasing the dose to 15 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3â€ƒâ€ƒRheumatoid <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></h2>
<p class="First"><a name="p1553122"></a>For the relief of the signs and symptoms
of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, the recommended starting and maintenance
oral dose of MOBIC is 7.5 mg once daily. Some patients may receive
additional benefit by increasing the dose to 15 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4â€ƒâ€ƒJuvenile Rheumatoid
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> (JRA) Pauciarticular and Polyarticular Course</h2>
<p class="First"><a name="p1561122"></a>To improve dosing accuracy in smaller weight
children, the use of the MOBIC oral suspension is recommended. MOBIC
oral suspension is available in the strength of 7.5 mg/5 mL. For the
treatment of <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span>, the recommended oral dose
of MOBIC is 0.125 mg/kg once daily up to a maximum of 7.5 mg. There
was no additional benefit demonstrated by increasing the dose above
0.125 mg/kg once daily in these clinical trials. </p>
<p><a name="p1564122"></a><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">Juvenile Rheumatoid Arthritis</span> dosing
using the oral suspension should be individualized based on the weight
of the child:</span></span></p>
<a name="t1571122"></a><table border="0" cellpadding="2" width="50%"><tbody class="Headless">
<tr class="First Toprule">
<td>Â </td>
<td align="center" colspan="2"><span class="Bold"><span class="Emphasis">0.125 mg/kg</span></span></td>
</tr>
<tr>
<td class="Toprule" valign="bottom"><span class="Bold"><span class="Emphasis">Weight</span></span></td>
<td class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">Dose<br>(1.5
mg/mL)</span></span></td>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Delivered dose</span></span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">12 kg (26 lb)</span></span></td>
<td class="Toprule">1.0 mL</td>
<td class="Toprule">1.5 mg</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">24 kg (54 lb)</span></span></td>
<td class="Toprule">2.0 mL</td>
<td class="Toprule">3.0 mg</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">36 kg (80 lb)</span></span></td>
<td class="Toprule">3.0 mL</td>
<td class="Toprule">4.5 mg</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">48 kg (106 lb)</span></span></td>
<td class="Toprule">4.0 mL</td>
<td class="Toprule">6.0 mg</td>
</tr>
<tr class="Last">
<td class="Toprule"><span class="Bold"><span class="Emphasis">â‰¥60 kg (132 lb)</span></span></td>
<td class="Toprule">5.0 mL</td>
<td class="Toprule">7.5 mg</td>
</tr>
</tbody></table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3â€ƒâ€ƒDOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><a name="p2314122"></a>Tablets:</p>
<ul class="Disc">
<li>7.5 mg: pastel yellow, round, biconvex, uncoated tablet
containing meloxicam 7.5 mg. Impressed with the Boehringer Ingelheim
logo on one side and the letter â€œMâ€? on the other.</li>
<li>15 mg: pastel yellow, oblong, biconvex, uncoated tablet
containing meloxicam 15 mg. Impressed with the tablet code â€œ15â€? on
one side and the letter â€œMâ€? on the other.</li>
</ul>
<p><a name="p2325122"></a>Oral Suspension: </p>
<ul class="Disc"><li>yellowish green tinged viscous suspension containing 7.5
mg meloxicam in 5 mL.</li></ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4â€ƒâ€ƒCONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1â€ƒâ€ƒAllergic Reactions</h2>
<p class="First"><a name="p2587122"></a>MOBIC is contraindicated in patients with
known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and serious
<span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>) to meloxicam.</p>
<p><a name="p2590122"></a>MOBIC should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>,
<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other
NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs
have been reported in such patients [<span class="Italics"><span class="Emphasis">see Warnings
and Precautions <a href="#Section_5.7">(5.7</a>, <a href="#Section_5.13">5.13)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2â€ƒâ€ƒCoronary Surgery</h2>
<p class="First"><a name="p2817122"></a>MOBIC is contraindicated for the treatment
of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft
(CABG) surgery [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.1">(5.1)</a></span></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5â€ƒâ€ƒWARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1â€ƒâ€ƒCardiovascular Thrombotic
Events</h2>
<p class="First"><a name="p3091122"></a>Clinical trials
of several COX-2 selective and nonselective NSAIDs of up to three
yearsâ€™ duration have shown an increased risk of serious cardiovascular
(CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can
be fatal. All NSAIDs, both COX-2 selective and nonselective, may have
a similar risk. Patients with known CV disease or risk factors for
CV disease may be at greater risk. To minimize the potential risk
for an adverse CV event in patients treated with an NSAID, the lowest
effective dose should be used for the shortest duration possible.
Physicians and patients should remain alert for the development of
such events, even in the absence of previous CV symptoms. Patients
should be informed about the signs and/or symptoms of serious CV events
and the steps to take if they occur.</p>
<p><a name="p3094122"></a>Two large, controlled, clinical trials of a COX-2 selective NSAID
for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10 to 14 days following CABG
surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> [<span class="Italics"><span class="Emphasis">see Contraindications <a href="#Section_4.2">(4.2)</a></span></span>].</p>
<p><a name="p3106122"></a>There is no consistent evidence that concurrent use of aspirin mitigates
the increased risk of serious CV thrombotic events associated with
NSAID use. The concurrent use of aspirin and an NSAID does increase
the risk of serious GI events [<span class="Italics"><span class="Emphasis">see Warnings and
Precautions <a href="#Section_5.2">(5.2)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2â€ƒâ€ƒGastrointestinal
(GI) Effects â€“ Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h2>
<p class="First"><a name="p3329122"></a>NSAIDs, including MOBIC, can cause serious
gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>,
ulceration, and perforation of the stomach, small intestine, or large
intestine, which can be fatal. These serious adverse events can occur
at any time, with or without warning symptoms, in patients treated
with NSAIDs. Only one in five patients who develop a serious upper
GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>,
gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs, occur in approximately
1% of patients treated for 3 to 6 months, and in about 2% to 4% of
patients treated for one year. These trends continue with longer duration
of use, increasing the likelihood of developing a serious GI event
at some time during the course of therapy. However, even short-term
therapy is not without risk.</p>
<p><a name="p3332122"></a>Prescribe
NSAIDs, including MOBIC, with extreme caution in those with a prior
history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with
a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>
who use NSAIDs have a greater than 10-fold increased risk for developing
a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors.
Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated
with NSAIDs include concomitant use of oral corticosteroids or anticoagulants,
longer duration of NSAID therapy, smoking, use of alcohol, older age,
and poor general health status. Most spontaneous reports of fatal
GI events are in elderly or debilitated patients and therefore, special
care should be taken in treating this population.</p>
<p><a name="p3335122"></a>To minimize the potential risk for an adverse GI event
in patients treated with an NSAID, use the lowest effective dose for
the shortest possible duration. Patients and physicians should remain
alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during
MOBIC therapy and promptly initiate additional evaluation and treatment
if a serious GI adverse event is suspected. This should include discontinuation
of MOBIC until a serious GI adverse event is ruled out. For high-risk
patients, consider alternate therapies that do not involve NSAIDs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3â€ƒâ€ƒHepatic Effects</h2>
<p class="First"><a name="p3343122"></a>Borderline elevations of one or more liver
tests may occur in up to 15% of patients taking NSAIDs including MOBIC.
These laboratory abnormalities may progress, may remain unchanged,
or may be transient with continuing therapy. Notable elevations of
ALT or AST (approximately three or more times the upper limit of normal)
have been reported in approximately 1% of patients in clinical trials
with NSAIDs. In addition, rare cases of severe hepatic reactions,
including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and
<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported
[<span class="Italics"><span class="Emphasis">see Adverse Reactions <a href="#Section_6.1">(6.1)</a></span></span>].</p>
<p><a name="p3355122"></a>A patient with symptoms and/or signs suggesting liver dysfunction,
or in whom an abnormal liver test has occurred, should be evaluated
for evidence of the development of a more severe hepatic reaction
while on therapy with MOBIC. If clinical signs and symptoms consistent
with liver disease develop, or if systemic manifestations occur (e.g.,
<span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), discontinue MOBIC [<span class="Italics"><span class="Emphasis">see
Use in Specific Populations <a href="#Section_8.6">(8.6)</a> and
Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4â€ƒâ€ƒHypertension</h2>
<p class="First"><a name="p3376122"></a>NSAIDs, including MOBIC, can lead to onset
of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either
of which may contribute to the increased incidence of CV events. NSAIDs,
including MOBIC, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.
Blood pressure (BP) should be monitored closely during the initiation
of NSAID treatment and throughout the course of therapy.</p>
<p><a name="p3585122"></a>Patients taking ACE inhibitors, thiazides,
or loop diuretics may have impaired response to these therapies when
taking NSAIDs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5â€ƒâ€ƒCongestive Heart
Failure and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><a name="p3593122"></a>Fluid
retention and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs.
Use MOBIC with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>,
or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6â€ƒâ€ƒRenal Effects</h2>
<p class="First"><a name="p3601122"></a>Long-term administration of NSAIDs, including
MOBIC, can result in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>,
<span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also
been seen in patients in whom renal prostaglandins have a compensatory
role in the maintenance of renal perfusion. In these patients, administration
of a nonsteroidal anti-inflammatory drug may cause a dose-dependent
reduction in prostaglandin formation and, secondarily, in renal blood
flow, which may precipitate overt renal decompensation. Patients at
greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>,
<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics, ACE-inhibitors,
and angiotensin II receptor antagonists, and the elderly. Discontinuation
of NSAID therapy is usually followed by recovery to the pretreatment
state.</p>
<p><a name="p3604122"></a>A pharmacokinetic study
in patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> revealed that
no dosage adjustments in these patient populations are required. Patients
with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> have not been studied. The use of MOBIC
in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with CrCl less than 20 mL/min
is not recommended. A study performed in patients on hemodialysis
revealed that although overall C<span class="Sub">max</span> was diminished
in this population, the proportion of free drug not bound to plasma
was increased. Therefore it is recommended that meloxicam dosage in
this population not exceed 7.5 mg per day. Closely monitor the renal
function of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> who are taking MOBIC
[<span class="Italics"><span class="Emphasis">see Dosage and Administration <a href="#Section_2.1">(2.1)</a>, Use in Specific Populations <a href="#Section_8.7">(8.7)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
<p><a name="p3628122"></a>Use caution when initiating treatment with MOBIC in patients with
considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. It is advisable to rehydrate patients first
and then start therapy with MOBIC. Caution is also recommended in
patients with pre-existing kidney disease.</p>
<p><a name="p3631122"></a>The extent to which metabolites may accumulate in patients
with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has not been studied with MOBIC. Because some
MOBIC metabolites are excreted by the kidney, monitor patients with
significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> closely.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7â€ƒâ€ƒAnaphylactoid Reactions</h2>
<p class="First"><a name="p3845122"></a>As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
have occurred in patients without known prior exposure to MOBIC. MOBIC
should not be given to patients with the aspirin triad. This symptom
complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>
with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal
<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs [<span class="Italics"><span class="Emphasis">see Contraindications <a href="#Section_4.1">(4.1)</a> and Warnings
and Precautions <a href="#Section_5.12">(5.12)</a></span></span>]. Seek emergency help in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>
occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8â€ƒâ€ƒAdverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First"><a name="p3866122"></a>NSAIDs, including MOBIC, can cause serious
skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, Stevens-Johnson
Syndrome (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be
fatal. These serious events may occur without warning. Inform patients
about the signs and symptoms of serious skin manifestations and discontinue
use of the drug at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other
sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9â€ƒâ€ƒPregnancy</h2>
<p class="First"><a name="p3874122"></a>Starting at 30 weeks gestation, avoid the
use of MOBIC because it may cause premature closure of the ductus
arteriosus [<span class="Italics"><span class="Emphasis">see Use in Specific Populations <a href="#Section_8.1">(8.1)</a> and Patient Counseling Information <a href="#Section_17.8">(17.8)</a></span></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10â€ƒâ€ƒCorticosteroid
Treatment</h2>
<p class="First"><a name="p4101122"></a>MOBIC cannot
be expected to substitute for corticosteroids or to treat corticosteroid
insufficiency. Abrupt discontinuation of corticosteroids may lead
to disease exacerbation. Slowly taper patients on prolonged corticosteroid
therapy if a decision is made to discontinue corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11â€ƒâ€ƒMasking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span>
and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></h2>
<p class="First"><a name="p4109122"></a>The pharmacological
activity of MOBIC in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish
the utility of these diagnostic signs in detecting complications of
presumed noninfectious, painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12â€ƒâ€ƒHematological Effects</h2>
<p class="First"><a name="p4117122"></a><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> may occur in patients receiving NSAIDs,
including MOBIC. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross
GI blood loss, or an incompletely described effect upon erythropoiesis.
Patients on long-term treatment with NSAIDs, including MOBIC, should
have their hemoglobin or hematocrit checked if they exhibit any signs
or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p><a name="p4120122"></a>NSAIDs
inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
time in some patients. Unlike aspirin, their effect on platelet function
is quantitatively less, of shorter duration, and reversible. Carefully
monitor patients treated with MOBIC who may be adversely affected
by alterations in platelet function, such as those with coagulation
disorders or patients receiving anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13â€ƒâ€ƒUse in Patients
with Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First"><a name="p4128122"></a>Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of
aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated
with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal. Since cross reactivity,
including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other NSAIDs has been
reported in such aspirin-sensitive patients, MOBIC should not be administered
to patients with this form of aspirin sensitivity and should be used
with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14â€ƒâ€ƒMonitoring</h2>
<p class="First"><a name="p4136122"></a>Because serious GI tract ulcerations and
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor
for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment
with NSAIDs should have their CBC and a chemistry profile checked
periodically. If clinical signs and symptoms consistent with liver
or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>,
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen, MOBIC should
be discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6â€ƒâ€ƒADVERSE REACTIONS</h1>
<p class="First"><a name="p4144122"></a>Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot
be directly compared to rates in the clinical trials of another drug
and may not reflect the rates observed in practice.</p>
<p><a name="p4353122"></a>The following serious adverse reactions are discussed
elsewhere in the labeling:</p>
<ul class="Disc">
<li>Cardiovascular thrombotic events [<span class="Italics"><span class="Emphasis">see
Boxed Warning and Warnings and Precautions <a href="#Section_5.1">(5.1)</a></span></span>]</li>
<li>Gastrointestinal effects â€“ risk of GI ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>,
and perforation [<span class="Italics"><span class="Emphasis">see Boxed Warning and Warnings
and Precautions <a href="#Section_5.2">(5.2)</a></span></span>]</li>
<li>Hepatic effects [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.3">(5.3)</a></span></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.4">(5.4)</a></span></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> [<span class="Italics"><span class="Emphasis">see
Warnings and Precautions <a href="#Section_5.5">(5.5)</a></span></span>]</li>
<li>Renal effects [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.6">(5.6)</a></span></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> [<span class="Italics"><span class="Emphasis">see Warnings
and Precautions <a href="#Section_5.7">(5.7)</a></span></span>]</li>
<li>Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> [<span class="Italics"><span class="Emphasis">see Warnings and
Precautions <a href="#Section_5.8">(5.8)</a></span></span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1â€ƒâ€ƒClinical Trials
Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.1"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Italics">Adults</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.1.1"></a><a name="section-6.1.1.1"></a><p></p>
<h4></h4>
<p class="First"><a name="p4903122"></a><span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and
<span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></span></span></p>
<p><a name="p4910122"></a>The MOBIC Phase 2/3 clinical trial database includes
10,122 OA patients and 1012 RA patients treated with MOBIC 7.5 mg/day,
3505 OA patients and 1351 RA patients treated with MOBIC 15 mg/day.
MOBIC at these doses was administered to 661 patients for at least
6 months and to 312 patients for at least one year. Approximately
10,500 of these patients were treated in ten placebo- and/or active-controlled
<span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> trials and 2363 of these patients were treated in ten
placebo- and/or active-controlled <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> trials. Gastrointestinal
(GI) adverse events were the most frequently reported adverse events
in all treatment groups across MOBIC trials.</p>
<p><a name="p4913122"></a>A 12-week multicenter, double-blind, randomized trial
was conducted in patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee or hip to
compare the efficacy and safety of MOBIC with placebo and with an
active control. Two 12-week multicenter, double-blind, randomized
trials were conducted in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> to compare
the efficacy and safety of MOBIC with placebo.</p>
<p><a name="p5122122"></a>Table 1a depicts adverse events that occurred in â‰¥2%
of the MOBIC treatment groups in a 12-week placebo- and active-controlled
<span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> trial.</p>
<p><a name="p5125122"></a>Table 1b
depicts adverse events that occurred in â‰¥2% of the MOBIC treatment
groups in two 12-week placebo-controlled <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> trials.</p>
<a name="t5128122"></a><table border="0" cellpadding="2" width="100%">
<caption><span>Table 1a Adverse Events (%) Occurring in â‰¥2% of MOBIC Patients
in a 12-Week <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> Placebo- and Active-Controlled Trial</span></caption>
<thead>
<tr class="First">
<th>Â </th>
<th><span class="Bold"><span class="Emphasis">Placebo</span></span></th>
<th><span class="Bold"><span class="Emphasis">MOBIC <br>7.5 mg daily</span></span></th>
<th><span class="Bold"><span class="Emphasis">MOBIC <br>15 mg daily</span></span></th>
<th><span class="Bold"><span class="Emphasis">Diclofenac <br>100 mg daily</span></span></th>
</tr>
<tr class="Last">
<th class="Toprule"><span class="Bold"><span class="Emphasis">No. of Patients</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">157</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">154</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">156</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">153</span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">1</span> WHO preferred terms <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>,
<span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">edema dependent</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema legs</span> combined<br><span class="Sup">2</span> WHO preferred terms <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous,
and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular combined</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><span class="Bold"><span class="Emphasis">Gastrointestinal</span></span></td>
<td class="Toprule">17.2</td>
<td class="Toprule">20.1</td>
<td class="Toprule">17.3</td>
<td class="Toprule">28.1</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Toprule">2.5</td>
<td class="Toprule">1.9</td>
<td class="Toprule">2.6</td>
<td class="Toprule">1.3</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Toprule">3.8</td>
<td class="Toprule">7.8</td>
<td class="Toprule">3.2</td>
<td class="Toprule">9.2</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Toprule">4.5</td>
<td class="Toprule">4.5</td>
<td class="Toprule">4.5</td>
<td class="Toprule">6.5</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Toprule">4.5</td>
<td class="Toprule">3.2</td>
<td class="Toprule">3.2</td>
<td class="Toprule">3.9</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Toprule">3.2</td>
<td class="Toprule">3.9</td>
<td class="Toprule">3.8</td>
<td class="Toprule">7.2</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Body as a Whole</span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">Accident</span> household</td>
<td>1.9</td>
<td>4.5</td>
<td>3.2</td>
<td>2.6</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><span class="Sup">1</span>
</td>
<td class="Toprule">2.5</td>
<td class="Toprule">1.9</td>
<td class="Toprule">4.5</td>
<td class="Toprule">3.3</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span></td>
<td class="Toprule">0.6</td>
<td class="Toprule">2.6</td>
<td class="Toprule">0.0</td>
<td class="Toprule">1.3</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td class="Toprule">5.1</td>
<td class="Toprule">4.5</td>
<td class="Toprule">5.8</td>
<td class="Toprule">2.6</td>
</tr>
<tr><td class="Toprule" colspan="6"><span class="Bold"><span class="Emphasis">Central and Peripheral <br>Nervous System</span></span></td></tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td>3.2</td>
<td>2.6</td>
<td>3.8</td>
<td>2.0</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Toprule">10.2</td>
<td class="Toprule">7.8</td>
<td class="Toprule">8.3</td>
<td class="Toprule">5.9</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Respiratory</span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td>1.3</td>
<td>0.6</td>
<td>3.2</td>
<td>1.3</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Toprule">1.9</td>
<td class="Toprule">3.2</td>
<td class="Toprule">1.9</td>
<td class="Toprule">3.3</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Skin </span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr class="Last">
<td> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">2</span>
</td>
<td>2.5</td>
<td>2.6</td>
<td>0.6</td>
<td>2.0</td>
</tr>
</tbody>
</table>
<a name="t7214122"></a><table border="0" cellpadding="2" width="100%">
<caption><span>Table 1bÂ Adverse Events (%) Occurring in â‰¥2% of MOBIC Patients
in two 12-Week <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> Placebo-Controlled Trials</span></caption>
<thead>
<tr class="First">
<th class="Toprule">Â </th>
<th valign="top"><span class="Bold"><span class="Emphasis">Placebo</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">MOBIC<br>7.5 mg daily</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">MOBIC<br>15 mg daily</span></span></th>
</tr>
<tr class="Last">
<th class="Toprule"><span class="Bold"><span class="Emphasis">No. of Patients</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">469</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">481</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">477</span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="4">
<span class="Sup">1</span>Â MedDRA high level term
(preferred terms): dyspeptic signs and symptoms (<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>
aggravated, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>), upper respiratory
tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>-pathogen unspecified (<span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span> NOS, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>
NOS, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> NOS), joint related signs and symptoms (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>,
<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia aggravated</span>, <span class="product-label-link" type="condition" conceptid="4100499" conceptname="Joint crepitus">joint crepitation</span>, <span class="product-label-link" type="condition" conceptid="72407" conceptname="Effusion of joint of shoulder region">joint effusion</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>)<br><span class="Sup">2</span>Â MedDRA preferred term: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, abdominal
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> NOS, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> NOS, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> NOS</td></tr></tfoot>
<tbody>
<tr class="First">
<td><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></span></td>
<td class="Toprule">14.1</td>
<td class="Toprule">18.9</td>
<td class="Toprule">16.8</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> NOS<span class="Sup">2</span>
</td>
<td class="Toprule">0.6</td>
<td class="Toprule">2.9</td>
<td class="Toprule">2.3</td>
</tr>
<tr>
<td class="Toprule">Dyspeptic signs and symptoms<span class="Sup">1</span>
</td>
<td class="Toprule">3.8</td>
<td class="Toprule">5.8</td>
<td class="Toprule">4.0</td>
</tr>
<tr>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><span class="Sup">2</span>
</td>
<td class="Toprule">2.6</td>
<td class="Toprule">3.3</td>
<td class="Toprule">3.8</td>
</tr>
<tr><td class="Toprule" colspan="5"><span class="Bold"><span class="Emphasis">General Disorders
and Administration Site Conditions</span></span></td></tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like illness<span class="Sup">2</span>
</td>
<td>2.1</td>
<td>2.9</td>
<td>2.3</td>
</tr>
<tr>
<td class="Toprule">
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></span><br><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span>-pathogen class
unspecified<span class="Sup">1</span>
</td>
<td class="Toprule" valign="bottom">4.1</td>
<td class="Toprule" valign="bottom">7.0</td>
<td class="Toprule" valign="bottom">6.5</td>
</tr>
<tr>
<td class="Toprule">
<span class="Bold"><span class="Emphasis">Musculoskeletal and Connective
Tissue Disorders</span></span><br>Joint related signs
and symptoms<span class="Sup">1</span>
</td>
<td class="Toprule" valign="bottom">1.9</td>
<td class="Toprule" valign="bottom">1.5</td>
<td class="Toprule" valign="bottom">2.3</td>
</tr>
<tr><td class="Toprule" colspan="5"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></span></td></tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> NOS<span class="Sup">2</span>
</td>
<td>6.4</td>
<td>6.4</td>
<td>5.5</td>
</tr>
<tr class="Last">
<td class="Toprule">
<span class="Bold"><span class="Emphasis">Skin and Subcutaneous Tissue Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> NOS<span class="Sup">2</span>
</td>
<td class="Toprule" valign="bottom">1.7</td>
<td class="Toprule" valign="bottom">1.0</td>
<td class="Toprule" valign="bottom">2.1</td>
</tr>
</tbody>
</table>
<p><a name="p8728122"></a>The adverse events that occurred
with MOBIC in â‰¥2% of patients treated short-term (4 to 6 weeks) and
long-term (6 months) in active-controlled <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> trials are
presented in Table 2.</p>
<a name="t8731122"></a><table border="0" cellpadding="2" width="100%">
<caption><span>Table 2 Adverse Events (%) Occurring in â‰¥2% of MOBIC Patients
in 4 to 6 Weeks and 6 Month Active-Controlled <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> Trials</span></caption>
<thead>
<tr class="First">
<th class="Toprule">Â </th>
<th colspan="2"><span class="Bold"><span class="Emphasis">4 to 6 Weeks Controlled Trials </span></span></th>
<th colspan="2"><span class="Bold"><span class="Emphasis">6 Month Controlled Trials</span></span></th>
</tr>
<tr>
<th class="Toprule">Â </th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">MOBIC<br>7.5 mg daily</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">MOBIC<br>15 mg daily</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">MOBIC<br>7.5 mg daily</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">MOBIC<br>15 mg daily</span></span></th>
</tr>
<tr class="Last">
<th class="Toprule"><span class="Bold"><span class="Emphasis">No. of Patients</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">8955</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">256</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">169</span></span></th>
<th class="Toprule"><span class="Bold"><span class="Emphasis">306</span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">1</span> WHO preferred terms <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>,
<span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">edema dependent</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema legs</span> combined<br><span class="Sup">2</span> WHO preferred terms <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous,
and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular combined</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><span class="Bold"><span class="Emphasis">Gastrointestinal </span></span></td>
<td class="Toprule">11.8</td>
<td class="Toprule">18.0</td>
<td class="Toprule">26.6</td>
<td class="Toprule">24.2</td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td class="Toprule">2.7</td>
<td class="Toprule">2.3</td>
<td class="Toprule">4.7</td>
<td class="Toprule">2.9</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td class="Toprule">0.8</td>
<td class="Toprule">1.2</td>
<td class="Toprule">1.8</td>
<td class="Toprule">2.6</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Toprule">1.9</td>
<td class="Toprule">2.7</td>
<td class="Toprule">5.9</td>
<td class="Toprule">2.6</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Toprule">3.8</td>
<td class="Toprule">7.4</td>
<td class="Toprule">8.9</td>
<td class="Toprule">9.5</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Toprule">0.5</td>
<td class="Toprule">0.4</td>
<td class="Toprule">3.0</td>
<td class="Toprule">2.6</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Toprule">2.4</td>
<td class="Toprule">4.7</td>
<td class="Toprule">4.7</td>
<td class="Toprule">7.2</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Toprule">0.6</td>
<td class="Toprule">0.8</td>
<td class="Toprule">1.8</td>
<td class="Toprule">2.6</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Body as a Whole</span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">Accident</span> household</td>
<td>0.0</td>
<td>0.0</td>
<td>0.6</td>
<td>2.9</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><span class="Sup">1</span>
</td>
<td class="Toprule">0.6</td>
<td class="Toprule">2.0</td>
<td class="Toprule">2.4</td>
<td class="Toprule">1.6</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Toprule">0.9</td>
<td class="Toprule">2.0</td>
<td class="Toprule">3.6</td>
<td class="Toprule">5.2</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Central and Peripheral <br>Nervous System</span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td>1.1</td>
<td>1.6</td>
<td>2.4</td>
<td>2.6</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Toprule">2.4</td>
<td class="Toprule">2.7</td>
<td class="Toprule">3.6</td>
<td class="Toprule">2.6</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">HematologicÂ Â </span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td>0.1</td>
<td>0.0</td>
<td>4.1</td>
<td>2.9</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Musculoskeletal</span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td>0.5</td>
<td>0.0</td>
<td>5.3</td>
<td>1.3</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Toprule">0.5</td>
<td class="Toprule">0.4</td>
<td class="Toprule">3.0</td>
<td class="Toprule">0.7</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Psychiatric</span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td>0.4</td>
<td>0.0</td>
<td>3.6</td>
<td>1.6</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Respiratory </span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td>0.2</td>
<td>0.8</td>
<td>2.4</td>
<td>1.0</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Toprule">0.2</td>
<td class="Toprule">0.0</td>
<td class="Toprule">8.3</td>
<td class="Toprule">7.5</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Skin</span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td>0.4</td>
<td>1.2</td>
<td>2.4</td>
<td>0.0</td>
</tr>
<tr>
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">2</span>
</td>
<td class="Toprule">0.3</td>
<td class="Toprule">1.2</td>
<td class="Toprule">3.0</td>
<td class="Toprule">1.3</td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Urinary </span></span></td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
<td class="Toprule">Â </td>
</tr>
<tr>
<td> Micturition frequency</td>
<td>0.1</td>
<td>0.4</td>
<td>2.4</td>
<td>1.3</td>
</tr>
<tr class="Last">
<td class="Toprule"> <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> </td>
<td class="Toprule">0.3</td>
<td class="Toprule">0.4</td>
<td class="Toprule">4.7</td>
<td class="Toprule">6.9</td>
</tr>
</tbody>
</table>
<p><a name="p12311122"></a>Higher doses of MOBIC (22.5 mg and
greater) have been associated with an increased risk of serious GI
events; therefore, the daily dose of MOBIC should not exceed 15 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.2"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Italics">Pediatrics</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.2.1"></a><a name="section-6.1.2.1"></a><p></p>
<h4></h4>
<p class="First"><a name="p12325122"></a><span class="Underline"><span class="Emphasis">Pauciarticular and
Polyarticular Course <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">Juvenile Rheumatoid Arthritis</span> (JRA)</span></span></p>
<p><a name="p12332122"></a>Three hundred and
eighty-seven patients with pauciarticular and polyarticular course
JRA were exposed to MOBIC with doses ranging from 0.125 to 0.375 mg/kg
per day in three clinical trials. These studies consisted of two 12-week
multicenter, double-blind, randomized trials (one with a 12-week open-label
extension and one with a 40-week extension) and one 1-year open-label
PK study. The adverse events observed in these pediatric studies with
MOBIC were similar in nature to the adult clinical trial experience,
although there were differences in frequency. In particular, the following
most common adverse events, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>,
and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, were more common in the pediatric than in the adult trials.
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> was reported in seven (&lt;2%) patients receiving MOBIC. No unexpected
adverse events were identified during the course of the trials. The
adverse events did not demonstrate an age or gender-specific subgroup
effect.</p>
<p><a name="p12336122"></a>The following is a list
of adverse drug reactions occurring in &lt;2% of patients receiving
MOBIC in clinical trials involving approximately 16,200 patients.</p>
<a name="t12545122"></a><table border="0" cellpadding="1" width="90%">
<colgroup>
<col width="30%">
<col width="70%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Emphasis">Body as a Whole</span></span></td>
<td><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>,
<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span> </td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Cardiovascular</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>,
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> </td>
</tr>
<tr>
<td class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">Central and Peripheral
Nervous System</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> </td>
</tr>
<tr>
<td class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">Gastrointestinal</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>,
<span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, gastrointestinal
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, hemorrhagic <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, hemorrhagic gastric
<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, perforated duodenal
<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, <span class="product-label-link" type="condition" conceptid="4057953" conceptname="Acute gastric ulcer with perforation">perforated gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="4260546" conceptname="Ulcerative stomatitis">stomatitis ulcerative</span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Heart Rate and Rhythm</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> </td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Hematologic</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> </td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Liver and Biliary System</span></span></td>
<td class="Toprule">ALT increased, AST increased, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, GGT
increased, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> </td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Metabolic and Nutritional</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Psychiatric </span></span></td>
<td class="Toprule">abnormal dreaming, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, appetite increased,
<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Respiratory</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Skin and Appendages</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>
reaction, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></td>
</tr>
<tr>
<td class="Toprule"><span class="Bold"><span class="Emphasis">Special Senses</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>,
<span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></td>
</tr>
<tr class="Last">
<td class="Toprule"><span class="Bold"><span class="Emphasis">Urinary System</span></span></td>
<td class="Toprule"><span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, BUN increased, creatinine increased,
<span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2â€ƒâ€ƒPost Marketing Experience</h2>
<p class="First"><a name="p13332122"></a>The following adverse reactions have been
identified during post approval use of MOBIC. Because these reactions
are reported voluntarily from a population of uncertain size, it is
not always possible to reliably estimate their frequency or establish
a causal relationship to drug exposure. Decisions about whether to
include an adverse event from spontaneous reports in labeling are
typically based on one or more of the following factors: (1) seriousness
of the event, (2) number of reports, or (3) strength of causal relationship
to the drug. Adverse reactions reported in worldwide post marketing
experience or the literature include: acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>;
alterations in mood (such as mood elevation); <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>; <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>; interstitial
<span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>; <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and
<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7â€ƒâ€ƒDRUG INTERACTIONS</h1>
<p class="First"><a name="p13340122"></a>See also Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1â€ƒâ€ƒACE-inhibitors</h2>
<p class="First"><a name="p13592122"></a>NSAIDs may diminish the antihypertensive
effect of ACE-inhibitors. This interaction should be given consideration
in patients taking MOBIC concomitantly with ACE-inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2â€ƒâ€ƒAspirin</h2>
<p class="First"><a name="p13600122"></a>When MOBIC is administered with aspirin
(1000 mg three times daily) to healthy volunteers, an increase in
the AUC (10%) and C<span class="Sub">max</span> (24%) of meloxicam was
noted. The clinical significance of this interaction is not known;
however, as with other NSAIDs concomitant administration of meloxicam
and aspirin is not generally recommended because of the potential
for increased adverse effects.</p>
<p><a name="p13607122"></a>Concomitant administration of low-dose aspirin with MOBIC may result
in an increased rate of GI ulceration or other complications, compared
to use of MOBIC alone. MOBIC is not a substitute for aspirin for cardiovascular
prophylaxis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3â€ƒâ€ƒDiuretics</h2>
<p class="First"><a name="p13615122"></a>Clinical studies, as well as post marketing
observations, have shown that NSAIDs can reduce the natriuretic effect
of furosemide and thiazides in some patients. This response has been
attributed to inhibition of renal prostaglandin synthesis. However,
studies with furosemide agents and meloxicam have not demonstrated
a reduction in natriuretic effect. Furosemide single and multiple
dose pharmacodynamics and pharmacokinetics are not affected by multiple
doses of meloxicam. Nevertheless, during concomitant therapy with
MOBIC, patients should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>
[<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.6">(5.6)</a></span></span>], as well as to ensure diuretic
efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4â€ƒâ€ƒLithium</h2>
<p class="First"><a name="p13838122"></a>In a study conducted in healthy subjects,
mean pre-dose lithium concentration and AUC were increased by 21%
in subjects receiving lithium doses ranging from 804 to 1072 mg twice
daily with meloxicam 15 mg every day as compared to subjects receiving
lithium alone. These effects have been attributed to inhibition of
renal prostaglandin synthesis by MOBIC. Closely monitor patients on
lithium treatment for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> when MOBIC is introduced,
adjusted, or withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5â€ƒâ€ƒMethotrexate</h2>
<p class="First"><a name="p13846122"></a>NSAIDs have been reported to competitively
inhibit methotrexate accumulation in rabbit kidney slices. Therefore,
NSAIDs may reduce the elimination of methotrexate, thereby enhancing
the toxicity of methotrexate. Use caution when MOBIC is administered
concomitantly with methotrexate [<span class="Italics"><span class="Emphasis">see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6â€ƒâ€ƒCyclosporine</h2>
<p class="First"><a name="p13863122"></a>MOBIC, like other NSAIDs, may affect renal
prostaglandins, thereby altering the renal toxicity of certain drugs.
Therefore, concomitant therapy with MOBIC may increase cyclosporine's
<span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Use caution when MOBIC is administered concomitantly
with cyclosporine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7â€ƒâ€ƒWarfarin</h2>
<p class="First"><a name="p13871122"></a>The effects of warfarin and NSAIDs on GI
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have
a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone.</p>
<p><a name="p14080122"></a>Monitor anticoagulant activity, particularly
in the first few days after initiating or changing MOBIC therapy in
patients receiving warfarin or similar agents, since these patients
are at an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> than with the use of either drug
alone. Use caution when administering MOBIC with warfarin since patients
on warfarin may experience changes in INR and an increased risk of
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications when a new medication is introduced [<span class="Italics"><span class="Emphasis">see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8â€ƒâ€ƒKayexalateÂ® (sodium
polystyrene sulfonate)</h2>
<p class="First"><a name="p14097122"></a>Cases of <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">intestinal necrosis</span> (possibly fatal) have been described
in patients who received concomitant sorbitol and KayexalateÂ® (sodium
polystyrene sulfonate).  Due to the presence of sorbitol in MOBIC
Oral Suspension, use with KayexalateÂ® is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8â€ƒâ€ƒUSE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1â€ƒâ€ƒPregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3></h3>
<p class="First"><a name="p14340122"></a><span class="Italics"><span class="Emphasis">Pregnancy Category C;
Category D starting 30 weeks gestation</span></span></p>
<p><a name="p14347122"></a>There are no adequate and well-controlled
studies in pregnant women. Meloxicam crosses the placental barrier.
Prior to 30 weeks gestation, use MOBIC during pregnancy only if the
potential benefit justifies the potential risk to the fetus. Starting
at 30 weeks gestation, avoid MOBIC and other NSAIDs, in pregnant women
as premature closure of the ductus arteriosus in the fetus may occur.
If this drug is used during this time period in pregnancy, inform
the patient of the potential hazard to a fetus [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.9">(5.9)</a> and Patient Counseling Information <a href="#Section_17.8">(17.8)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.1.2"></a><a name="section-8.1.2"></a><p></p>
<h3></h3>
<p class="First"><a name="p14367122"></a><span class="Italics"><span class="Emphasis">Teratogenic Effects</span></span></p>
<p><a name="p14374122"></a>Meloxicam was not
teratogenic when administered to pregnant rats during fetal organogenesis
at oral doses up to 4 mg/kg/day (2.6-fold greater than the maximum
recommended human daily dose [MRHD] based on body surface area [BSA]
comparison). Administration of meloxicam to pregnant rabbits throughout
embryogenesis produced an increased incidence of septal defects of
the heart at an oral dose of 60 mg/kg/day. The no effect level was
20 mg/kg/day (26-fold greater than the MRHD based on BSA conversion).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.1.3"></a><a name="section-8.1.3"></a><p></p>
<h3></h3>
<p class="First"><a name="p14381122"></a><span class="Italics"><span class="Emphasis">Nonteratogenic Effects</span></span></p>
<p><a name="p14594122"></a>In rats and rabbits,
embryolethality occurred at oral meloxicam doses of 1 mg/kg/day and
5 mg/kg/day, respectively (0.65- and 6.5-fold greater, respectively,
than the MRHD based on BSA comparison) when administered throughout
organogenesis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2â€ƒâ€ƒLabor and Delivery</h2>
<p class="First"><a name="p14602122"></a>The effects of MOBIC on labor and delivery of pregnant women are
unknown. Oral administration of meloxicam to pregnant rats during
late gestation through lactation increased the incidence of dystocia,
delayed parturition, and decreased offspring survival at meloxicam
doses of 0.125 mg/kg/day or greater (at least 12.5 times lower than
the maximum recommended human daily dose based on body surface area
comparison).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3â€ƒâ€ƒNursing Mothers</h2>
<p class="First"><a name="p14610122"></a>It is not known whether this drug is excreted in human milk; however,
meloxicam was excreted in the milk of lactating rats at concentrations
higher than those in plasma. Because many drugs are excreted in human
milk and because of the potential for serious adverse reactions in
nursing infants from MOBIC, a decision should be made whether to discontinue
nursing or to discontinue the drug, taking into account the importance
of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4â€ƒâ€ƒPediatric Use</h2>
<p class="First"><a name="p14618122"></a>The safety and effectiveness of meloxicam in pediatric JRA patients
from 2 to 17 years of age has been evaluated in three clinical trials
[<span class="Italics"><span class="Emphasis">see Dosage and Administration <a href="#Section_2.3">(2.3)</a>, Adverse Reactions <a href="#Section_6.1">(6.1)</a>, and Clinical Studies <a href="#Section_14.2">(14.2)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5â€ƒâ€ƒGeriatric Use</h2>
<p class="First"><a name="p14849122"></a>As with any NSAID, caution should be exercised in treating the elderly
(65 years and older).</p>
<p><a name="p14852122"></a>Of the
total number of subjects in clinical studies, 5157 were age 65 and
over (4044 in OA studies and 1113 in RA studies). No overall differences
in safety or effectiveness were observed between these subjects and
younger subjects, and other reported clinical experience has not identified
differences in responses between the elderly and younger patients,
but greater sensitivity of some older individuals cannot be ruled
out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6â€ƒâ€ƒHepatic Impairment</h2>
<p class="First"><a name="p14860122"></a>No dose adjustment is necessary in patients
with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients with severe hepatic
impairment have not been adequately studied. Since meloxicam is significantly
metabolized in the liver; the use of meloxicam in these patients should
be done with caution [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.3">(5.3)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7â€ƒâ€ƒRenal Impairment</h2>
<p class="First"><a name="p14881122"></a>No dose adjustment is necessary in patients
with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with severe renal
impairment have not been studied. The use of MOBIC in subjects with
severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended. Following a single dose
of meloxicam, the free C<span class="Sub">max</span> plasma concentrations
were higher in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> on chronic hemodialysis
(1% free fraction) in comparison to healthy volunteers (0.3% free
fraction). Therefore, it is recommended that meloxicam dosage in this
population not exceed 7.5 mg per day. Hemodialysis did not lower the
total drug concentration in plasma; therefore, additional doses are
not necessary after hemodialysis. Meloxicam is not dialyzable [<span class="Italics"><span class="Emphasis">see Dosage and Administration <a href="#Section_2.1">(2.1)</a>, Warnings and Precautions <a href="#Section_5.6">(5.6)</a>, and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.8"></a><a name="section-8.8"></a><p></p>
<h2>8.8â€ƒâ€ƒFemales of Reproductive Potential</h2>
<p class="First"><a name="p322841122"></a>Data from several small studies in humans and from
studies in animals indicate that NSAIDs, including MOBIC, may be associated
with a reversible delay in ovulation. Therefore, in women who have
difficulties conceiving, or who are undergoing investigation of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>,
use of meloxicam is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10â€ƒâ€ƒOVERDOSAGE</h1>
<p class="First"><a name="p15116122"></a>There
is limited experience with meloxicam <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Four cases have taken
6 to 11 times the highest recommended dose; all recovered. Cholestyramine
is known to accelerate the clearance of meloxicam.</p>
<p><a name="p15119122"></a>Symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>,
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally
reversible with supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur.
Severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may result in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>,
hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, cardiovascular
collapse, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported
with therapeutic ingestion of NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p><a name="p15122122"></a>Patients should be managed with symptomatic
and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Administration of
activated charcoal is recommended for patients who present 1 to 2
hours after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. For substantial <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or severely symptomatic
patients, activated charcoal may be administered repeatedly. Accelerated
removal of meloxicam by 4 g oral doses of cholestyramine given three
times a day was demonstrated in a clinical trial. Administration of
cholestyramine may be useful following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>,
alkalinization of urine, hemodialysis, or hemoperfusion may not be
useful due to high protein binding.</p>
<p><a name="p15125122"></a>For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment, call a poison
control center (1-800-222-1222).</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11â€ƒâ€ƒDESCRIPTION</h1>
<p class="First"><a name="p15133122"></a>Meloxicam, an oxicam derivative, is a member
of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs).
Each pastel yellow MOBIC tablet contains 7.5 mg or 15 mg meloxicam
for oral administration. Each bottle of MOBIC oral suspension contains
7.5 mg meloxicam per 5 mL. Meloxicam is chemically designated as 4-hydroxy-2-methyl-<span class="Italics">N</span>-(5-methyl-2-thiazolyl)-2<span class="Italics">H</span>-1,2-benzothiazine-3-carboxamide-1,1-dioxide.
The molecular weight is 351.4. Its empirical formula is C<span class="Sub">14</span>H<span class="Sub">13</span>N<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span> and it has the
following structural formula:</p>
<div class="Figure"><img alt="Mobic Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=676e73fb-51d2-449a-8749-1a7bcc257b11&amp;name=mobic-tab-struct.jpg"></div>
<p><a name="p15372122"></a>Meloxicam is a pastel yellow solid, practically insoluble
in water, with higher solubility observed in strong acids and bases.
It is very slightly soluble in methanol. Meloxicam has an apparent
partition coefficient (log P)<span class="Sub">app</span> = 0.1 in <span class="Italics">n</span>-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1
and 4.2.</p>
<p><a name="p15383122"></a>MOBIC is available as
a tablet for oral administration containing 7.5 mg or 15 mg meloxicam,
and as an oral suspension containing 7.5 mg meloxicam per 5 mL.</p>
<p><a name="p15386122"></a>The inactive ingredients in MOBIC tablets
include colloidal silicon dioxide, crospovidone, lactose monohydrate,
magnesium stearate, microcrystalline cellulose, povidone, and sodium
citrate dihydrate.</p>
<p><a name="p15389122"></a>The inactive
ingredients in MOBIC oral suspension include colloidal silicon dioxide,
hydroxyethylcellulose, sorbitol, glycerol, xylitol, monobasic sodium
phosphate (dihydrate), saccharin sodium, sodium benzoate, citric acid
(monohydrate), raspberry flavor, and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12â€ƒâ€ƒCLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1â€ƒâ€ƒMechanism of Action</h2>
<p class="First"><a name="p15402122"></a>The mechanism of action of meloxicam, like that of other NSAIDs,
may be related to prostaglandin synthetase (cyclo-oxygenase) inhibition
which is involved in the initial steps of the arachidonic acid cascade,
resulting in the reduced formation of prostaglandins, thromboxanes
and prostacylin. It is not completely understood how reduced synthesis
of these compounds results in therapeutic efficacy.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2â€ƒâ€ƒPharmacodynamics</h2>
<p class="First"><a name="p15616122"></a>Meloxicam exhibits anti-inflammatory, analgesic, and antipyretic
activities.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3â€ƒâ€ƒPharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.1"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Italics">Absorption</span></h3>
<p class="First"><a name="p15631122"></a>The absolute bioavailability
of meloxicam capsules was 89% following a single oral dose of 30 mg
compared with 30 mg IV bolus injection. Following single intravenous
doses, dose-proportional pharmacokinetics were shown in the range
of 5 mg to 60 mg. After multiple oral doses the pharmacokinetics of
meloxicam capsules were dose-proportional over the range of 7.5 mg
to 15 mg. Mean C<span class="Sub">max</span> was achieved within four
to five hours after a 7.5 mg meloxicam tablet was taken under fasted
conditions, indicating a prolonged drug absorption. With multiple
dosing, steady-state concentrations were reached by Day 5. A second
meloxicam concentration peak occurs around 12 to 14 hours post-dose
suggesting biliary recycling.</p>
<p><a name="p15638122"></a>Meloxicam oral suspension doses of 7.5 mg/5 mL and 15 mg/10 mL have
been found to be bioequivalent to meloxicam 7.5 mg and 15 mg capsules,
respectively. Meloxicam capsules have been shown to be bioequivalent
to MOBIC tablets.</p>
<a name="t15641122"></a><table border="0" cellpadding="2" width="100%">
<caption><span>Table 3 Single Dose and Steady-State Pharmacokinetic Parameters
for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)<span class="Sup">1</span></span></caption>
<thead>
<tr class="First">
<th class="Toprule" valign="top">Â </th>
<th class="Toprule" valign="top">Â </th>
<th class="Toprule" colspan="3" valign="top"><span class="Bold"><span class="Emphasis">Steady
State</span></span></th>
<th class="Toprule" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">Single
Dose</span></span></th>
</tr>
<tr>
<th colspan="2" valign="top"><span class="Bold"><span class="Emphasis">Pharmacokinetic<br>Parameters<br>Â (% CV)</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">Healthy male adults<br>	 (Fed)<span class="Sup">2</span></span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">Elderly males<br>(Fed)<span class="Sup">2</span></span></span></th>
<th class="Rrule Toprule" valign="top"><span class="Bold"><span class="Emphasis">Elderly females
(Fed)<span class="Sup">2</span></span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> (Fasted)</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic insufficiency</span>
(Fasted)</span></span></th>
</tr>
<tr>
<th class="Toprule" valign="top">Â </th>
<th class="Toprule" valign="top">Â </th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">7.5 mg<span class="Sup">3</span> tablets</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">15 mg capsules</span></span></th>
<th class="Rrule Toprule" valign="top"><span class="Bold"><span class="Emphasis">15 mg capsules</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">15 mg capsules</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">15 mg capsules</span></span></th>
</tr>
<tr class="Last">
<th class="Toprule" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">N</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">18</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">5</span></span></th>
<th class="Rrule Toprule" valign="top"><span class="Bold"><span class="Emphasis">8</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">12</span></span></th>
<th class="Toprule" valign="top"><span class="Bold"><span class="Emphasis">12</span></span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="7">
<span class="Bold"><span class="Emphasis"><span class="Sup">1</span></span></span>The parameter values in the table are from various studies<br><span class="Bold"><span class="Emphasis"><span class="Sup">2 </span></span></span>not
under high fat conditions<br><span class="Bold"><span class="Emphasis"><span class="Sup">3 </span></span></span>MOBIC tablets<br><span class="Bold"><span class="Emphasis"><span class="Sup">4 </span></span></span>V<span class="Sub">z</span>/f =Dose/(AUCâ€¢K<span class="Sub">el</span>)</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" valign="top">C<span class="Sub">max</span>
</td>
<td class="Toprule" valign="top">[Âµg/mL]</td>
<td class="Toprule" valign="top">1.05 (20)</td>
<td class="Toprule" valign="top">2.3 (59)</td>
<td class="Rrule Toprule" valign="top">3.2 (24)</td>
<td class="Toprule" valign="top">0.59 (36)</td>
<td class="Toprule" valign="top">0.84 (29)</td>
</tr>
<tr>
<td class="Toprule" valign="top">t<span class="Sub">max</span>
</td>
<td class="Toprule" valign="top">[h]</td>
<td class="Toprule" valign="top">4.9 (8)</td>
<td class="Toprule" valign="top">5 (12)</td>
<td class="Rrule Toprule" valign="top">6 (27)</td>
<td class="Toprule" valign="top">4 (65)</td>
<td class="Toprule" valign="top">10 (87)</td>
</tr>
<tr>
<td class="Toprule" valign="top">t<span class="Sub">1/2</span>
</td>
<td class="Toprule" valign="top">[h]</td>
<td class="Toprule" valign="top">20.1 (29)</td>
<td class="Toprule" valign="top">21 (34)</td>
<td class="Rrule Toprule" valign="top">24 (34)</td>
<td class="Toprule" valign="top">18 (46)</td>
<td class="Toprule" valign="top">16 (29)</td>
</tr>
<tr>
<td class="Toprule" valign="top">CL/f</td>
<td class="Toprule" valign="top">[mL/min]</td>
<td class="Toprule" valign="top">8.8 (29)</td>
<td class="Toprule" valign="top">9.9 (76)</td>
<td class="Rrule Toprule" valign="top">5.1 (22)</td>
<td class="Toprule" valign="top">19 (43)</td>
<td class="Toprule" valign="top">11 (44)</td>
</tr>
<tr class="Last">
<td class="Toprule" valign="top">V<span class="Sub">z</span>/f<span class="Sup">4</span>
</td>
<td class="Toprule" valign="top">[L]</td>
<td class="Toprule" valign="top">14.7 (32)</td>
<td class="Toprule" valign="top">15 (42)</td>
<td class="Rrule Toprule" valign="top">10 (30)</td>
<td class="Toprule" valign="top">26 (44)</td>
<td class="Toprule" valign="top">14 (29)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.2"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Italics">Food and Antacid
Effects</span></h3>
<p class="First"><a name="p17678122"></a>Administration
of meloxicam capsules following a high fat breakfast (75 g of fat)
resulted in mean peak drug levels (i.e., C<span class="Sub">max</span>) being increased by approximately 22% while the extent of absorption
(AUC) was unchanged. The time to maximum concentration (T<span class="Sub">max</span>) was achieved between 5 and 6 hours. In comparison,
neither the AUC nor the C<span class="Sub">max</span> values for meloxicam
suspension were affected following a similar high fat meal, while
mean T<span class="Sub">max</span> values were increased to approximately
7 hours. No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was detected with concomitant
administration of antacids. Based on these results, MOBIC can be administered
without regard to timing of meals or concomitant administration of
antacids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.3"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Italics">Distribution</span></h3>
<p class="First"><a name="p17704122"></a>The mean volume of
distribution (Vss) of meloxicam is approximately 10 L. Meloxicam is
~99.4% bound to human plasma proteins (primarily albumin) within the
therapeutic dose range. The fraction of protein binding is independent
of drug concentration, over the clinically relevant concentration
range, but decreases to ~99% in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Meloxicam
penetration into human red blood cells, after oral dosing, is less
than 10%. Following a radiolabeled dose, over 90% of the radioactivity
detected in the plasma was present as unchanged meloxicam.</p>
<p><a name="p17707122"></a>Meloxicam concentrations in synovial fluid,
after a single oral dose, range from 40% to 50% of those in plasma.
The free fraction in synovial fluid is 2.5 times higher than in plasma,
due to the lower albumin content in synovial fluid as compared to
plasma. The significance of this penetration is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.4"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Italics">Metabolism</span></h3>
<p class="First"><a name="p17923122"></a>Meloxicam is extensively
metabolized in the liver. Meloxicam metabolites include 5'-carboxy
meloxicam (60% of dose), from P-450 mediated metabolism formed by
oxidation of an intermediate metabolite 5'-hydroxymethyl meloxicam
which is also excreted to a lesser extent (9% of dose). <span class="Italics">In
vitro</span> studies indicate that CYP2C9 (cytochrome P450 metabolizing
enzyme) plays an important role in this metabolic pathway with a minor
contribution of the CYP3A4 isozyme. Patientsâ€™ peroxidase activity
is probably responsible for the other two metabolites which account
for 16% and 4% of the administered dose, respectively. All the four
metabolites are not known to have any <span class="Italics">in vivo</span> pharmacological
activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.5"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Italics">Excretion</span></h3>
<p class="First"><a name="p17941122"></a>Meloxicam excretion
is predominantly in the form of metabolites, and occurs to equal extents
in the urine and feces.  Only traces of the unchanged parent compound
are excreted in the urine (0.2%) and feces (1.6%).  The extent of
the urinary excretion was confirmed for unlabeled multiple 7.5 mg
doses: 0.5%, 6%, and 13% of the dose were found in urine in the form
of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites,
respectively.  There is significant biliary and/or enteral secretion
of the drug.  This was demonstrated when oral administration of cholestyramine
following a single IV dose of meloxicam decreased the AUC of meloxicam
by 50%.</p>
<p><a name="p17944122"></a>The mean elimination
half-life (t<span class="Sub">1/2</span>) ranges from 15 hours to 20
hours. The elimination half-life is constant across dose levels indicating
linear metabolism within the therapeutic dose range.  Plasma clearance
ranges from 7 to 9 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Italics">Special Populations</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.1"></a><a name="section-11.3.6.1"></a><p></p>
<h4></h4>
<p class="First"><a name="p17962122"></a><span class="Underline"><span class="Emphasis">Pediatric</span></span></p>
<p><a name="p17969122"></a>After single (0.25 mg/kg) dose administration and after achieving
steady state (0.375 mg/kg/day), there was a general trend of approximately
30% lower exposure in younger patients (2 to 6 years old) as compared
to the older patients (7 to 16 years old).  The older patients had
meloxicam exposures similar (single dose) or slightly reduced (steady
state) to those in the adult patients, when using AUC values normalized
to a dose of 0.25 mg/kg [<span class="Italics"><span class="Emphasis">see Dosage and Administration <a href="#Section_2.4">(2.4)</a></span></span>].  The meloxicam
mean (SD) elimination half-life was 15.2 (10.1) and 13.0 hours (3.0)
for the 2 to 6 year old patients, and 7 to 16 year old patients, respectively.</p>
<p><a name="p18187122"></a>In a covariate analysis, utilizing population
pharmacokinetics body-weight, but not age, was the single predictive
covariate for differences in the meloxicam apparent oral plasma clearance.
 The body-weight normalized apparent oral clearance values were adequate
predictors of meloxicam exposure in pediatric patients. </p>
<p><a name="p18190122"></a>The pharmacokinetics of MOBIC in pediatric
patients under 2 years of age have not been investigated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.2"></a><a name="section-11.3.6.2"></a><p></p>
<h4></h4>
<p class="First"><a name="p18197122"></a><span class="Underline"><span class="Emphasis">Geriatric</span></span></p>
<p><a name="p18204122"></a>Elderly males (â‰¥65 years of age) exhibited meloxicam plasma concentrations
and steady-state pharmacokinetics similar to young males.  Elderly
females (â‰¥65 years of age) had a 47% higher AUC<span class="Sub">ss</span> and 32% higher C<span class="Sub">max,ss</span> as compared to younger
females (â‰¤55 years of age) after body weight normalization.  Despite
the increased total concentrations in the elderly females, the adverse
event profile was comparable for both elderly patient populations.
 A smaller free fraction was found in elderly female patients in comparison
to elderly male patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.3"></a><a name="section-11.3.6.3"></a><p></p>
<h4></h4>
<p class="First"><a name="p18219122"></a><span class="Underline"><span class="Emphasis">Gender</span></span></p>
<p><a name="p18432122"></a>Young females exhibited slightly lower plasma concentrations relative
to young males.  After single doses of 7.5 mg MOBIC, the mean elimination
half-life was 19.5 hours for the female group as compared to 23.4
hours for the male group.  At steady state, the data were similar
(17.9 hours vs 21.4 hours).  This pharmacokinetic difference due to
gender is likely to be of little clinical importance.  There was linearity
of pharmacokinetics and no appreciable difference in the C<span class="Sub">max</span> or T<span class="Sub">max</span> across genders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.4"></a><a name="section-11.3.6.4"></a><p></p>
<h4></h4>
<p class="First"><a name="p18447122"></a><span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p><a name="p18454122"></a>Following a single 15 mg dose of meloxicam there was
no marked difference in plasma concentrations in patients with mild
(Child-Pugh Class I) or moderate (Child-Pugh Class II) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>
compared to healthy volunteers.  Protein binding of meloxicam was
not affected by <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  No dosage adjustment is necessary
in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  Patients with
severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class III) have not been adequately
studied [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.3">(5.3)</a> and Use in Specific Populations <a href="#Section_8.6">(8.6)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.5"></a><a name="section-11.3.6.5"></a><p></p>
<h4></h4>
<p class="First"><a name="p18474122"></a><span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p><a name="p18481122"></a>Meloxicam pharmacokinetics have been investigated in
subjects with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Total drug plasma
concentrations of meloxicam decreased and total clearance of meloxicam
increased with the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> while free AUC values
were similar in all groups. The higher meloxicam clearance in subjects
with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> may be due to increased fraction of unbound
meloxicam which is available for hepatic metabolism and subsequent
excretion.  No dosage adjustment is necessary in patients with mild
to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>
have not been adequately studied.  The use of MOBIC in subjects with
severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended [<span class="Italics"><span class="Emphasis">see
Warnings and Precautions <a href="#Section_5.6">(5.6)</a> and
Use in Specific Populations <a href="#Section_8.7">(8.7)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.6"></a><a name="section-11.3.6.6"></a><p></p>
<h4></h4>
<p class="First"><a name="p18707122"></a><span class="Underline"><span class="Emphasis">Hemodialysis</span></span></p>
<p><a name="p18714122"></a>Following a single dose of meloxicam, the free C<span class="Sub">max</span> plasma concentrations were higher in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>
on chronic hemodialysis (1% free fraction) in comparison to healthy
volunteers (0.3% free fraction).  Hemodialysis did not lower the total
drug concentration in plasma; therefore, additional doses are not
necessary after hemodialysis.  Meloxicam is not dialyzable [<span class="Italics"><span class="Emphasis">see Dosage and Administration <a href="#Section_2.1">(2.1)</a>, Warnings and Precautions <a href="#Section_5.6">(5.6)</a>, and Use in Specific Populations <a href="#Section_8.7">(8.7)</a></span></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.7"></a><a name="section-11.3.7"></a><p></p>
<h3><span class="Italics">Drug Interactions</span></h3>
<p class="First"><a name="p18951122"></a><span class="Italics"><span class="Emphasis">Aspirin:</span></span>  When MOBIC is administered with aspirin
(1000 mg three times daily) to healthy volunteers, it tended to increase
the AUC (10%) and C<span class="Sub">max</span> (24%) of meloxicam.
 The clinical significance of this interaction is not known [<span class="Italics"><span class="Emphasis">see Drug Interactions <a href="#Section_7.2">(7.2)</a></span></span>].</p>
<p><a name="p18972122"></a><span class="Italics"><span class="Emphasis">Cholestyramine:</span></span> Pretreatment for four
days with cholestyramine significantly increased the clearance of
meloxicam by 50%.  This resulted in a decrease in t<span class="Sub">1/2</span>, from 19.2 hours to 12.5 hours, and a 35% reduction in AUC.  This
suggests the existence of a recirculation pathway for meloxicam in
the gastrointestinal tract.  The clinical relevance of this interaction
has not been established.</p>
<p><a name="p18984122"></a><span class="Italics"><span class="Emphasis">Cimetidine:</span></span> Concomitant administration
of 200 mg cimetidine four times daily did not alter the single-dose
pharmacokinetics of 30 mg meloxicam.</p>
<p><a name="p18992122"></a><span class="Italics"><span class="Emphasis">Digoxin:</span></span> Meloxicam 15 mg once
daily for 7 days did not alter the plasma concentration profile of
digoxin after Î²-acetyldigoxin administration for 7 days at clinical
doses.  <span class="Italics">In vitro</span> testing found no protein binding
drug interaction between digoxin and meloxicam.</p>
<p><a name="p19210122"></a><span class="Italics"><span class="Emphasis">Lithium:</span></span> In a
study conducted in healthy subjects, mean pre-dose lithium concentration
and AUC were increased by 21% in subjects receiving lithium doses
ranging from 804 to 1072 mg twice daily with meloxicam 15 mg QD every
day as compared to subjects receiving lithium alone [<span class="Italics"><span class="Emphasis">see Drug Interactions <a href="#Section_7.4">(7.4)</a></span></span>].</p>
<p><a name="p19227122"></a><span class="Italics"><span class="Emphasis">Methotrexate:</span></span> A study in 13 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>
(RA) patients evaluated the effects of multiple doses of meloxicam
on the pharmacokinetics of methotrexate taken once weekly.  Meloxicam
did not have a significant effect on the pharmacokinetics of single
doses of methotrexate.  <span class="Italics">In vitro</span>, methotrexate did
not displace meloxicam from its human serum binding sites [<span class="Italics"><span class="Emphasis">see Drug Interactions <a href="#Section_7.5">(7.5)</a></span></span>].</p>
<p><a name="p19248122"></a><span class="Italics"><span class="Emphasis">Warfarin:</span></span> The effect of meloxicam on
the anticoagulant effect of warfarin was studied in a group of healthy
subjects receiving daily doses of warfarin that produced an INR (International
Normalized Ratio) between 1.2 and 1.8.  In these subjects, meloxicam
did not alter warfarin pharmacokinetics and the average anticoagulant
effect of warfarin as determined by <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.  However, one
subject showed an increase in INR from 1.5 to 2.1.  Caution should
be used when administering MOBIC with warfarin since patients on warfarin
may experience changes in INR and an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications
when a new medication is introduced [<span class="Italics"><span class="Emphasis">see Drug Interactions <a href="#Section_7.7">(7.7)</a></span></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13â€ƒâ€ƒNONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1â€ƒâ€ƒCarcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="p19481122"></a><span class="Italics">Carcinogenesis</span>: There
was no increase in tumor incidence in long-term carcinogenicity studies
in rats (104 weeks) and mice (99 weeks) administered meloxicam at
oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg/day in
mice (up to 0.5- and 2.6-fold, respectively, the maximum recommended
human daily dose based on body surface area comparison).</p>
<p><a name="p19487122"></a><span class="Italics">Mutagenesis</span>: Meloxicam
was not mutagenic in an Ames assay, or clastogenic in a chromosome
aberration assay with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and an <span class="Italics">in vivo</span> micronucleus test in mouse bone marrow.  </p>
<p><a name="p19497122"></a><span class="Italics">Impairment of Fertility</span>: Meloxicam
did not impair male and female fertility in rats at oral doses up
to 9 mg/kg/day in males and 5 mg/kg/day in females (up to 5.8- and
3.2-fold greater, respectively, than the maximum recommended human
daily dose based on body surface area comparison).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14â€ƒâ€ƒCLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1â€ƒâ€ƒOsteoarthritis
and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First"><a name="p19719122"></a>The use of MOBIC for the treatment of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>
of the knee and hip was evaluated in a 12-week, double-blind, controlled
trial.  MOBIC (3.75 mg, 7.5 mg, and 15 mg daily) was compared to placebo.
 The four primary endpoints were investigatorâ€™s global assessment,
patient global assessment, patient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> assessment, and total WOMAC
score (a self-administered questionnaire addressing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, function,
and <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>).  Patients on MOBIC 7.5 mg daily and MOBIC 15 mg daily
showed significant improvement in each of these endpoints compared
with placebo.</p>
<p><a name="p19722122"></a>The use of MOBIC
for the management of signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> was evaluated
in six double-blind, active-controlled trials outside the U.S. ranging
from 4 weeksâ€™ to 6 monthsâ€™ duration.  In these trials, the efficacy
of MOBIC, in doses of 7.5 mg/day and 15 mg/day, was comparable to
piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with
the efficacy seen in the U.S. trial.  </p>
<p><a name="p19725122"></a>The use of MOBIC for the treatment of the signs and
symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> was evaluated in a 12-week, double-blind,
controlled multinational trial.  MOBIC (7.5 mg, 15 mg, and 22.5 mg
daily) was compared to placebo.  The primary endpoint in this study
was the ACR20 response rate, a composite measure of clinical, laboratory,
and functional measures of RA response.  Patients receiving MOBIC
7.5 mg and 15 mg daily showed significant improvement in the primary
endpoint compared with placebo.  No incremental benefit was observed
with the 22.5 mg dose compared to the 15 mg dose.	</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2â€ƒâ€ƒJuvenile Rheumatoid
<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> (JRA) Pauciarticular and Polyarticular Course</h2>
<p class="First"><a name="p19733122"></a>The use of MOBIC for the treatment of the
signs and symptoms of pauciarticular or polyarticular course Juvenile
<span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> in patients 2 years of age and older was evaluated
in two 12-week, double-blind, parallel-arm, active-controlled trials.</p>
<p><a name="p19736122"></a>Both studies included three arms: naproxen
and two doses of meloxicam.  In both studies, meloxicam dosing began
at 0.125 mg/kg/day (7.5 mg maximum) or 0.25 mg/kg/day (15 mg maximum),
and naproxen dosing began at 10 mg/kg/day.  One study used these doses
throughout the 12-week dosing period, while the other incorporated
a titration after 4 weeks to doses of 0.25 mg/kg/day and 0.375 mg/kg/day
(22.5 mg maximum) of meloxicam and 15 mg/kg/day of naproxen.</p>
<p><a name="p19739122"></a>The efficacy analysis used the ACR Pediatric
30 responder definition, a composite of parent and investigator assessments,
counts of active joints and joints with limited range of motion, and
<span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span>.  The proportion of responders were
similar in all three groups in both studies, and no difference was
observed between the meloxicam dose groups. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16â€ƒâ€ƒHOW SUPPLIED/STORAGE
AND HANDLING</h1>
<p class="First"><a name="p19747122"></a>MOBIC is
available as a pastel yellow, round, biconvex, uncoated tablet containing
meloxicam 7.5 mg or as a pastel yellow, oblong, biconvex, uncoated
tablet containing meloxicam 15 mg.  The 7.5 mg tablet is impressed
with the Boehringer Ingelheim logo on one side, and on the other side,
the letter â€œMâ€?.  The 15 mg tablet is impressed with the tablet code
â€œ15â€? on one side and the letter â€œMâ€? on the other.  MOBIC is also available
as a yellowish green tinged viscous oral suspension containing 7.5
mg meloxicam in 5 mL.</p>
<p><a name="p19750122"></a>MOBIC tablets
7.5 mg:  NDC 0597-0029-01; Bottles of 100</p>
<p><a name="p19753122"></a>MOBIC tablets 15 mg:  NDC 0597-0030-01; Bottles of
100</p>
<p><a name="p19756122"></a>MOBIC oral suspension 7.5
mg/5 mL:  NDC 0597-0034-01; Bottles of 100 mL</p>
<div class="Section" data-sectionCode="44425-7">
<a name="Section_16.1"></a><a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First"><a name="p19969122"></a><span class="Italics"><span class="Emphasis">Storage</span></span></p>
<p><a name="p19976122"></a><span class="Bold"><span class="Emphasis">Store at 25Â°C (77Â°F); excursions permitted to 15Â°C-30Â°C
(59Â°F-86Â°F).</span></span>  Keep MOBIC tablets in a dry place.</p>
<p><a name="p19984122"></a>Dispense tablets in a tight container.
 Keep oral suspension container tightly closed.</p>
<p><a name="p19987122"></a>Keep this and all medications out of the reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17â€ƒâ€ƒPATIENT COUNSELING INFORMATION</h1>
<p class="First"><a name="p19995122"></a><span class="Italics"><span class="Emphasis">See FDA-approved Medication Guide</span></span></p>
<p><a name="p20002122"></a><span class="Bold"><span class="Emphasis">Patients
should be informed of the following information before initiating
therapy with an NSAID and periodically during the course of ongoing
therapy.  </span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1â€ƒâ€ƒMedication Guide</h2>
<p class="First"><a name="p20014122"></a>Inform patients of the availability of
a Medication Guide for NSAIDs that accompanies each prescription dispensed,
and instruct them to read the Medication Guide prior to using MOBIC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2â€ƒâ€ƒCardiovascular
Effects</h2>
<p class="First"><a name="p20228122"></a>NSAIDs including
MOBIC may cause serious CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which
may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV
events can occur without warning symptoms, patients should be alert
for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>,
slurring of speech, and should ask for medical advice when observing
any indicative sign or symptoms. Patients should be apprised of the
importance of this follow-up [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.1">(5.1)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3â€ƒâ€ƒGastrointestinal
Effects</h2>
<p class="First"><a name="p20245122"></a>NSAIDs including
MOBIC, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects,
such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and
even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can
occur without warning symptoms, patients should be alert for the signs
and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical
advice when observing any indicative sign or symptoms including epigastric
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised
of the importance of this follow-up [<span class="Italics"><span class="Emphasis">see Warnings
and Precautions <a href="#Section_5.2">(5.2)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4â€ƒâ€ƒHepatotoxicity</h2>
<p class="First"><a name="p20262122"></a>Inform patients of the warning signs and
symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>,
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like" symptoms).
If these occur, instruct patients to stop therapy and seek immediate
medical therapy [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.3">(5.3)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5â€ƒâ€ƒAdverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First"><a name="p20485122"></a>NSAIDs including MOBIC, can cause serious
skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, Stevens-Johnson
Syndrome (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which may result
in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>
may occur without warning, patients should be alert for the signs
and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>
such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing
any indicative signs or symptoms. Advise patients to stop the drug
immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians
as soon as possible [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.8">(5.8)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6â€ƒâ€ƒWeight Gain and
<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><a name="p20502122"></a>Advise patients
to promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or
<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.5">(5.5)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.7"></a><a name="section-15.7"></a><p></p>
<h2>17.7â€ƒâ€ƒAnaphylactoid Reactions </h2>
<p class="First"><a name="p20519122"></a>Inform patients of the signs of an anaphylactoid
reaction (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat).
 Instruct patients seek immediate emergency help [<span class="Italics"><span class="Emphasis">see Warnings and Precautions <a href="#Section_5.7">(5.7)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.8"></a><a name="section-15.8"></a><p></p>
<h2>17.8â€ƒâ€ƒEffects During
Pregnancy</h2>
<p class="First"><a name="p20742122"></a>Starting at
30 weeks gestation, MOBIC should be avoided as premature closure of
the ductus arteriosus in the fetus may occur [<span class="Italics"><span class="Emphasis">see
Warnings and Precautions <a href="#Section_5.9">(5.9)</a> and
Use in Specific Populations <a href="#Section_8.1">(8.1)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36377522"></a><a name="section-15.9"></a><p></p>
<h2>17.9â€ƒâ€ƒEffects on Female Fertility</h2>
<p class="First"><a name="p322781422"></a>Advise females of reproductive potential who desire
pregnancy that NSAIDs, including MOBIC, may be associated with a reversible
delay in ovulation. For women who have difficulties conceiving, or
who are undergoing investigation of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, use of meloxicam
is not recommended [<span class="Italics">see Use in Specific Populations <a href="#Section_8.8">(8.8)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><a name="p20762122"></a>Kayexalate is a registered trademark of
Sanofi-Aventis</p>
<p><a name="p20765122"></a><span class="Bold"><span class="Emphasis">Please address medical inquiries to (800) 542-6257 or (800) 459-9906
TTY.</span></span></p>
<p><a name="p20772122"></a>Distributed
by: Boehringer Ingelheim Pharmaceuticals, Inc.<br>Ridgefield,
CT 06877 USA</p>
<p><a name="p20777122"></a>Licensed from: Boehringer
Ingelheim International GmbH</p>
<p><a name="p20780122"></a>Copyright 2012 Boehringer Ingelheim International GmbH<br>ALL RIGHTS RESERVED</p>
<p><a name="p20785122"></a>10003990/08<br>IT1400KC122012</p>
<p><a name="p20996122"></a>090340141/9<br>OT1407G</p>
<p><a name="p21001122"></a></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_19"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><a name="p21007122"></a><span class="Emphasis"><span class="Bold">Medication Guide for Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs)</span><br><span class="Underline">(See
the end of this Medication Guide for a list of prescription NSAID
medicines.)</span></span></p>
<p><a name="p21018122"></a><span class="Bold"><span class="Emphasis">What is the most important information I should know
about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></span></p>
<p><a name="p21025122"></a><span class="Bold"><span class="Emphasis">NSAID
medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that
can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></span> This chance increases:</p>
<ul class="Disc">
<li>with longer use of NSAID medicines</li>
<li>in people who have heart disease</li>
</ul>
<p><a name="p21041122"></a><span class="Bold"><span class="Emphasis">NSAID medicines should
never be used right before or after a heart surgery called a "coronary
artery bypass graft (CABG)."</span></span></p>
<p><a name="p21254122"></a><span class="Bold"><span class="Emphasis">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and
<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment.
<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></span></p>
<ul class="Disc">
<li>can happen without warning symptoms</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><a name="p21269122"></a><span class="Bold"><span class="Emphasis">The chance of a person
getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span></span></p>
<ul class="Disc">
<li>taking medicines called "corticosteroids" and "anticoagulants"</li>
<li>longer use</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>having poor health</li>
</ul>
<p><a name="p21296122"></a><span class="Bold"><span class="Emphasis">NSAID medicines should
only be used:</span></span></p>
<ul class="Disc">
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<a name="t21520122"></a><table border="0" width="100%"><tbody class="Headless"><tr class="First Last Toprule"><td class="Botrule">Â </td></tr></tbody></table>
<p><a name="p21529122"></a><span class="Bold"><span class="Emphasis">What are Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs)?</span></span></p>
<p><a name="p21536122"></a>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>,
<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul class="Disc">
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<a name="t21547122"></a><table border="0" width="100%"><tbody class="Headless"><tr class="First Last Toprule"><td class="Botrule">Â </td></tr></tbody></table>
<p><a name="p21762122"></a><span class="Bold"><span class="Emphasis">Who should not take
a Non-Steroidal Anti-Inflammatory Drug (NSAID)? <br> Do not
take an NSAID medicine:</span></span></p>
<ul class="Disc">
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>
with aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><a name="p21779122"></a><span class="Bold"><span class="Emphasis">Tell your healthcare
provider:</span></span></p>
<ul class="Disc">
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take. NSAIDs and some other
medicines can interact with each other and cause serious side effects. <span class="Bold"><span class="Emphasis">Keep a list of your medicines to show to your healthcare
provider and pharmacist.</span></span>
</li>
<li>if you are pregnant. <span class="Bold"><span class="Emphasis">NSAID medicines should
not be used by pregnant women late in their pregnancy.</span></span>
</li>
<li>if you are breastfeeding. <span class="Bold"><span class="Emphasis">Talk to your doctor.</span></span>
</li>
</ul>
<a name="t22021122"></a><table border="0" width="100%"><tbody class="Headless"><tr class="First Last Toprule"><td class="Botrule">Â </td></tr></tbody></table>
<p><a name="p22030122"></a><span class="Bold"><span class="Emphasis">What are the possible
side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></span></p>
<p><a name="p22037122"></a><span class="Bold"><span class="Emphasis">Serious
side effects include:</span></span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul>
<p><a name="p22285122"></a><span class="Bold"><span class="Emphasis">Other side effects
include:</span></span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
<p><a name="p22318122"></a><span class="Bold"><span class="Emphasis">Get emergency help
right away if you have any of the following symptoms:</span></span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul>
<p><a name="p22548122"></a><span class="Bold"><span class="Emphasis">Stop your NSAID medicine
and call your healthcare provider right away if you have any of the
following symptoms:</span></span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
<li>there is blood in your bowel movement or it is black and
sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul>
<p><a name="p22796122"></a>These are not all the side effects
with NSAID medicines. Talk to your healthcare provider or pharmacist
for more information about NSAID medicines.</p>
<p><a name="p22799122"></a><span class="Bold"><span class="Emphasis">Call your doctor for medical advice
about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></span></p>
<p><a name="p22806122"></a><span class="Bold"><span class="Emphasis">Other
information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></span></p>
<ul class="Disc">
<li>Aspirin is an NSAID medicine but it does not increase the
chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain,
stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach
and intestines. </li>
<li>Some of these NSAID medicines are sold in lower doses without
a prescription (over-the-counter). Talk to your healthcare provider
before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<p><a name="p22821122"></a><span class="Bold"><span class="Emphasis"><span class="Underline">NSAID
medicines that need a prescription</span></span></span></p>
<a name="t22830122"></a><table border="1" cellpadding="1" width="100%">
<colgroup>
<col width="25%">
<col width="75%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td valign="bottom"><span class="Bold"><span class="Emphasis">Generic Name</span></span></td>
<td valign="bottom"><span class="Bold"><span class="Emphasis">Tradename</span></span></td>
</tr>
<tr>
<td valign="top">Celecoxib</td>
<td valign="top">Celebrex</td>
</tr>
<tr>
<td valign="top">Diclofenac</td>
<td valign="top">Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
</tr>
<tr>
<td valign="top">Diflunisal</td>
<td valign="top">Dolobid</td>
</tr>
<tr>
<td valign="top">Etodolac</td>
<td valign="top">Lodine, Lodine XL</td>
</tr>
<tr>
<td valign="top">Fenoprofen</td>
<td valign="top">Nalfon, Nalfon 200</td>
</tr>
<tr>
<td valign="top">Flurbiprofen</td>
<td valign="top">Ansaid</td>
</tr>
<tr>
<td valign="top">Ibuprofen</td>
<td valign="top">Motrin, Tab-Profen, Vicoprofen* (combined with hydrocodone),
Combunox (combined with oxycodone)</td>
</tr>
<tr>
<td valign="top">Indomethacin</td>
<td valign="top">Indocin, Indocin SR, <br>Indo-Lemmon, Indomethagan</td>
</tr>
<tr>
<td valign="top">Ketoprofen</td>
<td valign="top">Oruvail</td>
</tr>
<tr>
<td valign="top">Ketorolac</td>
<td valign="top">Toradol</td>
</tr>
<tr>
<td valign="top">Mefenamic Acid</td>
<td valign="top">Ponstel</td>
</tr>
<tr>
<td valign="top">Meloxicam</td>
<td valign="top">Mobic</td>
</tr>
<tr>
<td valign="top">Nabumetone</td>
<td valign="top">Relafen</td>
</tr>
<tr>
<td valign="top">Naproxen</td>
<td valign="top">Naprosyn, Anaprox, Anaprox DS, EC-Naprosyn, Naprelan,
Naprapac (copackaged with lansoprazole)</td>
</tr>
<tr>
<td valign="top">Oxaprozin</td>
<td valign="top">Daypro</td>
</tr>
<tr>
<td valign="top">Piroxicam</td>
<td valign="top">Feldene</td>
</tr>
<tr>
<td valign="top">Sulindac</td>
<td valign="top">Clinoril</td>
</tr>
<tr class="Last">
<td valign="top">Tolmetin</td>
<td valign="top">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p><a name="p23824122"></a>*Vicoprofen contains the same dose
of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used
for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.Â  The OTC NSAID label warns that
long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p><a name="p23827122"></a><span class="Italics"><span class="Emphasis">This
Medication Guide has been approved by the U.S. Food and Drug Administration.</span></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g6f0889db-9941-e121-826b-5752b062a9f1"></a><a name="section-18"></a><p></p>
<p class="First"><a name="p123220617"></a>Mobic<span class="Sup">Â®</span> (meloxicam) Tablets Label<br>7.5 mg/100 Tablets<br>NDC: 0597Â­0029Â­01</p>
<div class="Figure"><img alt="Mobic 7.5mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=676e73fb-51d2-449a-8749-1a7bcc257b11&amp;name=label002901.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g8c2448e1-d262-dd2b-0ef7-ea480569ad0c"></a><a name="section-19"></a><p></p>
<p class="First"><a name="p12322345000000"></a>Mobic<span class="Sup">Â®</span> (meloxicam) Tablets Label<br>15 mg/100 Tablets<br>NDC: 0597Â­0030Â­01</p>
<div class="Figure"><img alt="Mobic 15mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=676e73fb-51d2-449a-8749-1a7bcc257b11&amp;name=label003001.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="g5f6b83b7-5e60-9ab5-ae54-815611bb703f"></a><a name="section-20"></a><p></p>
<p class="First"><a name="p12322"></a>Mobic<span class="Sup">Â®</span> (meloxicam) Oral Suspension<br>7.5 mg/5 mL<br>NDCL: 0597Â­0034Â­01</p>
<div class="Figure"><img alt="Mobic Oral Suspension Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=676e73fb-51d2-449a-8749-1a7bcc257b11&amp;name=carton003401.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOBICÂ 		
					</strong><br><span class="contentTableReg">meloxicam suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0034</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MELOXICAM</strong> (MELOXICAM) </td>
<td class="formItem">MELOXICAM</td>
<td class="formItem">7.5Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYETHYL CELLULOSE (2000 CPS AT 1%)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>XYLITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0034-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 BOTTLE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021530</td>
<td class="formItem">11/01/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOBICÂ 		
					</strong><br><span class="contentTableReg">meloxicam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0029</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MELOXICAM</strong> (MELOXICAM) </td>
<td class="formItem">MELOXICAM</td>
<td class="formItem">7.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0029-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020938</td>
<td class="formItem">06/01/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOBICÂ 		
					</strong><br><span class="contentTableReg">meloxicam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0597-0030</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MELOXICAM</strong> (MELOXICAM) </td>
<td class="formItem">MELOXICAM</td>
<td class="formItem">15Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Oblong) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0597-0030-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020938</td>
<td class="formItem">10/01/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Boehringer Ingelheim Pharmaceuticals, Inc.
							(603175944)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Boehringer Ingelheim Pharmaceuticals, Inc. (603175944)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane Inc.</td>
<td class="formItem"></td>
<td class="formItem">058839929</td>
<td class="formItem">PACK(0597-0030, 0597-0034, 0597-0029), LABEL(0597-0029, 0597-0034, 0597-0030), ANALYSIS(0597-0034), MANUFACTURE(0597-0034)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Promeco S.A. de C.V.</td>
<td class="formItem"></td>
<td class="formItem">812579472</td>
<td class="formItem">ANALYSIS(0597-0030, 0597-0029), MANUFACTURE(0597-0030, 0597-0029), PACK(0597-0030, 0597-0029), LABEL(0597-0029, 0597-0030)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Roxane, Inc.</td>
<td class="formItem"></td>
<td class="formItem">002655556</td>
<td class="formItem">ANALYSIS(0597-0034)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH and Co. KG</td>
<td class="formItem"></td>
<td class="formItem">551147440</td>
<td class="formItem">ANALYSIS(0597-0030, 0597-0029), MANUFACTURE(0597-0030, 0597-0029)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bidachem S.p.A.</td>
<td class="formItem"></td>
<td class="formItem">429232812</td>
<td class="formItem">ANALYSIS(0597-0030, 0597-0029, 0597-0034), API MANUFACTURE(0597-0030, 0597-0029, 0597-0034)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Boehringer Ingelheim Pharma GmbH and Co. KG</td>
<td class="formItem"></td>
<td class="formItem">340700520</td>
<td class="formItem">ANALYSIS(0597-0030, 0597-0029, 0597-0034), API MANUFACTURE(0597-0030, 0597-0029, 0597-0034)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9f17db91-a8af-1e89-b992-d6a31be324a6</div>
<div>Set id: 676e73fb-51d2-449a-8749-1a7bcc257b11</div>
<div>Version: 9</div>
<div>Effective Time: 20120315</div>
</div>
</div>Â <div class="DistributorName">Boehringer Ingelheim Pharmaceuticals, Inc.</div></p>
</body></html>
